Antibody titers in mice immunized with naked PSII polysaccharide or PSII-CRM197 conjugate
MVX02: A multivalent vaccine targeting a bacterial cell surface polysaccharide and toxins A and B
All prophylactic vaccine candidates in development have targeted toxins A and B, the primary causes of disease symptoms.
Matrivax is doing something different!
We are developing MVX02, a vaccine candidate that targets the PSII polysaccharide, an antigen found on all C. difficile strain cell surfaces, and toxins A and B. Neutralization of toxins A and B coupled with the concurrent reduction in bacterial colonization will synergize towards a more efficacious vaccine.
Our preclinical animal models show that the PSII-protein (CRM197) conjugate is immunogenic and reduces bacterial colonization, and a vaccine combining PSII-protein conjugate and toxoids A and B confers improved animal protection over toxoid A/B vaccination upon C. difficile challenge.
A vaccine is needed for prevention of C. difficile disease
The standard of care for patients experiencing Clostridiodes difficile infection (CDI), commonly termed antibiotic-associated diarrhea, is antibiotic therapy which ironically can create further harmful unbalancing of the intestinal microbiota and lead to antibiotic resistance. There is a pressing need to develop and implement alternative prophylactic and therapeutic options to prevent and/or treat CDI.
Many C. difficile vaccine candidates have been tested in large, late-phase clinical trials but currently, there are no approved vaccines for CDI.